Another study, which tested the immunogenicity of an experimental heterologous adenovirus 5 (Ad5) and VACV-based malaria vaccine, demonstrated that increasing the prime-boost interval from 2 weeks (the peak of T cell expansion) to 8 weeks also enhanced CD8 T cell immunity and provided greater protection against challenge [39]. The gene discussed is CD8A; the disease is malaria.